Neil Kumar Singla
Chief Medical OfficerDr. Neil Kumar Singla, MD, is Chief Medical Officer of Latigo Biotherapeutics, Inc. from April 2024. He serves as the Chief Executive Officer of Lotus Clinical Research located in Pasadena, California. He served as Chief Scientific Officer at Lotus Clinical Research, LLC. He served as Member of GTX-101 Scientific Advisory Board at Acasti Pharma Inc. since August 2021 until 2022. Dr. Singla also serves as the Director of Clinical Research and Vice Chairman of the Institutional Review Board at Huntington Memorial Hospital. Dr. Singla serves as a Member of Medical Advisory Board at AcelRx Pharmaceuticals, Inc. Dr. Singla is Board certified in Anesthesiology and has published extensively in multiple anesthesia journals and trade magazines. He is a compassionate patient advocate who works tirelessly toward the advancement of novel pain management strategies. In his capacity as CSO for Lotus Clinical Research, Dr. Singla has had the opportunity to interact frequently with the FDA’s Analgesics Division on behalf of clients and to play a significant role in guiding development strategies for dozens of putative analgesic agents. In the company’s 18-year history, Dr. Singla and Lotus Clinical Research have played a significant role in bringing several molecules to market. He is a frequent lecturer for physicians, pharmaceutical companies and medical research institutes throughout the country. Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies and medical research institutes throughout the country. He chairs the Analgesic Clinical Trials Shared/Special Interest Group at the International Association for the Study of Pain (IASP), chaired the Clinical Trials Shared Interest Group at the American Pain Society (APS) through 2019, chairs the annual Conference on Analgesic Clinical Trials, which aims to help experts advance best practices in analgesic drug development, as well as, serving on the Clinical Research Committee at Huntington Hospital. The main focus of Dr. Singla’s academic endeavors has been to analyze and understand how the inherent variability in subjective endpoint analgesic clinical trials can be minimized. As a result, he has developed novel techniques for patient education designed to minimize variability, reduce placebo response and increase effect size. Dr. Singla earned his B.S. in Biology from the University of Akron and his M.D. at Northeast Ohio Medical University.
Positions
- Company NameLatigo Biotherapeutics, Inc.Stock CodeLTGOPositionChief Medical OfficerColleagues
- NKNeha KrishnamohanChief Business Officer & CFO
- TPTimothy P. WalbertIndependent Chairman
- NFNima FarzanExecutive Officer
- TNTodd N. SmithPresIdent, CEO & Director
- JCJulia ChapmanSenior Vice President of Operations
- BCBeth C. SeidenbergIndependent Director
- SMSara M. BonsteinIndependent Director
- DPDeborah PalestrantIndependent Director
